In a patient post‑acute myocardial infarction with successful revascularization, left‑ventricular ejection fraction ≥50% and no other indication for beta‑blockade, how should chronic oral beta‑blocker therapy be tapered or discontinued?

Beta-Blocker Tapering After Uncomplicated MI with Preserved LVEF

In patients post-acute myocardial infarction with successful revascularization and LVEF ≥50% without other indications for beta-blockade, beta-blockers should be discontinued after 12 months, as long-term continuation provides no mortality or cardiovascular benefit in this population.

Guideline Framework

The 2023 ACC/AHA Chronic Coronary Disease Guideline fundamentally changed the approach to beta-blockers in this population. Long-term beta-blocker therapy is not recommended to improve outcomes in patients with chronic coronary disease in the absence of myocardial infarction in the past year, left ventricular ejection fraction ≤50%, or another primary indication for beta-blocker therapy 1, 2. This represents a major departure from older guidelines that recommended 3-year treatment courses 3, 4.

The 2025 ACC/AHA/SCAI Acute Coronary Syndromes Guideline reinforces early initiation (within 24 hours) of oral beta-blockers to reduce reinfarction and ventricular arrhythmias during the acute phase 5, but the chronic phase recommendations align with the 2023 guidance for preserved LVEF patients.

Evidence Supporting Discontinuation

The most compelling recent evidence comes from five major randomized controlled trials published between 2024-2025, all conducted in the modern reperfusion era:

The 2025 individual patient-level meta-analysis of 17,801 patients with LVEF ≥50% post-MI found no benefit from beta-blockers 6. During 3.6 years median follow-up, the composite of death, MI, or heart failure occurred in 8.1% with beta-blockers versus 8.3% without (HR 0.97,95% CI 0.87-1.07, P=0.54). Importantly, individual components showed no benefit: death (HR 1.04), MI (HR 0.89), or heart failure (HR 0.87).

The REBOOT trial (8,438 patients, Spain/Italy) demonstrated that beta-blocker therapy versus no beta-blocker resulted in identical rates of death, reinfarction, or heart failure hospitalization (22.5 vs 21.7 events per 1000 patient-years; HR 1.04) 7.

The REDUCE-AMI trial (5,020 patients, Sweden/Estonia/New Zealand) with LVEF ≥50% showed no difference in death or new MI (7.9% vs 8.3%; HR 0.96) over 3.5 years 8.

Practical Discontinuation Approach

Timing

• Discontinue at 12 months post-MI for uncomplicated cases with LVEF ≥50%
• Earlier discontinuation may be considered if side effects are problematic, though the ABYSS trial suggested potential increased risk with very early discontinuation 9

Tapering Method

While the trials used abrupt discontinuation without reported rebound phenomena, a conservative approach in clinical practice:

1. Reduce dose by 50% for 1-2 weeks
2. Then discontinue completely
3. Monitor for 2-4 weeks for symptom recurrence

Contraindications to Discontinuation

Do NOT discontinue if patient has:

• LVEF <50% (continue indefinitely) 1, 2
• Heart failure symptoms (continue indefinitely) 4, 10
• Hypertension requiring beta-blocker control
• Atrial fibrillation requiring rate control
• Angina symptoms (beta-blockers remain first-line antianginal therapy alongside calcium channel blockers) 1
• Prior ventricular arrhythmias

Subgroup Considerations

STEMI patients may warrant more caution. One observational study suggested potential increased risk with discontinuation after STEMI (aHR 1.46) compared to NSTEMI (aHR 0.70, P-interaction=0.033) 11. However, the BETAMI trial specifically in STEMI patients with LVEF ≥40% showed benefit from continuation (HR 0.85 for death or MACE) 12, though this included patients with LVEF 40-49%.

For LVEF 40-49% (mildly reduced): The evidence is less clear. The BETAMI trial included this group and showed benefit 12. Consider continuing beta-blockers in this borderline group, particularly after STEMI.

Common Pitfalls

1. Continuing beta-blockers indefinitely out of habit - The pre-reperfusion era data no longer applies to modern revascularized patients with preserved LVEF
2. Confusing "preserved LVEF" thresholds - The new evidence uses ≥50%; older guidelines used ≥40%
3. Failing to reassess other indications - Before discontinuing, confirm no hypertension, angina, or arrhythmia requiring beta-blockade
4. Abrupt discontinuation in high-dose patients - Though trials showed safety, clinical prudence suggests tapering

Monitoring After Discontinuation

• Blood pressure check at 2-4 weeks
• Assess for angina recurrence
• Monitor heart rate if patient has history of tachycardia
• No routine stress testing needed unless symptoms develop 1

The convergence of multiple high-quality RCTs from 2024-2025, combined with updated guideline recommendations, provides strong evidence that routine long-term beta-blocker therapy after uncomplicated MI with preserved LVEF is unnecessary and can be safely discontinued at 12 months.